Liver Mac OS
Coputer-assisted liver surgery. Contribute to mjirik/lisa development by creating an account on GitHub. Coputer-assisted liver surgery. Contribute to mjirik/lisa development by creating an account on GitHub. See our install notes for Linux, Mac OS and Windows. Or use experimental windows installer. Install stable branche on Linux or Mac. Liver injury can arise due to genetics, viruses, lifestyle or exposure to drugs and other chemicals in the environment. In fact, most cases of acute liver failure in the U.S. Are due to drugs. Unfortunately, therapy for liver damage is limited, and methods used currently to predict which drugs are likely to cause liver injury are inadequate.
Medically reviewed by Drugs.com. Last updated on March 16, 2020.
French fries and burgers are a poor choice to keep your liver healthy. Eat too many foods that are high in saturated fat and it can make it harder for your liver to do its job. Ketogenic diet is an effective treatment for nonalcoholic fatty liver disease (NAFLD). Here, we present evidence that hepatic mitochondrial fluxes and redox state are markedly altered during ketogenic diet-induced reversal of NAFLD in humans. Ketogenic diet for 6 d markedly decreased liver fat content and hepatic insulin resistance. These changes were associated with increased net hydrolysis.
Applies to the following strengths: 500 mg; 750 mg; 100 mg/mL
Usual Adult Dose for:
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Muscle Spasm
ORAL:
Initial Dose: 1500 mg orally 4 times a day
-Doses of 6000 mg per day are generally used for the first 48 to 72 hours
-In severe cases, doses up to 8000 mg per day may be used
Maintenance dose:
500 mg tablets: 1000 mg orally 4 times a day
750 mg Tablets: 750 mg orally every 4 hours OR 1500 mg orally 3 times a day
PARENTERAL:
-For the relief of moderate symptoms: 1 g IV or IM once, then switch to oral
-For relief of severe symptoms or postoperative conditions: 1 g IV or IM every 8 hours
Maximum Dose: 3 g in 24-hours
Maximum Duration: 3 consecutive days; may repeat after a drug-free interval of 48 hours
Comments:
-Higher doses are recommended in the first 48 to 72 hours of treatment, then doses can usually be reduced to approximately 4000 mg per day.
-Oral tablets should be administered whenever feasible; IV/IM therapy should not be administered for more than 3 consecutive days without a drug-free interval of 48 hours.
Use: As an adjunct to rest and physical therapy for the relief of discomfort associated with acute, painful musculoskeletal conditions.
Usual Adult Dose for Tetanus
Initial dose: 1 to 2 g IV followed by an additional 1 to 2 g via IV infusion
Maximal Initial Dose: 3 g
Repeat initial IV dose every 6 hours until NG tube or oral therapy is possible
Once NG tube is in place, may crush tablets, suspend in water or saline and administer through tube
-Total oral doses of up to 24 g may be needed based on patient response
Comments:
-There is clinical evidence to suggest this drug may have a beneficial effect in the control of the neuromuscular manifestations of tetanus.
-This drug should not replace the usual procedure of debridement, tetanus antitoxin, penicillin, tracheotomy, attention to fluid balance, and supportive care; if used, this drug should be added to the regimen as soon as possible.
Use: To control the neuromuscular manifestations of tetanus.
Usual Pediatric Dose for Tetanus
Initial dose: 15 mg/kg or 500 mg/m2 IV; repeat initial dose every 6 hours as needed
Maximum dose: 1.8 g/m2/day IV for 3 consecutive days
Maintenance dose: May be given by injection into tubing or by IV infusion with an appropriate quantity of fluid
Comments:
-There is clinical evidence to suggest this drug may have a beneficial effect in the control of the neuromuscular manifestations of tetanus.
-This drug should not replace the usual procedure of debridement, tetanus antitoxin, penicillin, tracheotomy, attention to fluid balance, and supportive care; if used, this drug should be added to the regimen as soon as possible.
Use: To control the neuromuscular manifestations of tetanus.
Renal Dose Adjustments
Oral therapy: No adjustment recommended
Injectable therapy: Not recommended in patients with renal insufficiency due to the high concentration of polyethylene glycol in the solution
Liver Dose Adjustments
Use with caution, dose adjustment may be required, especially in patients with cirrhosis; however, no specific guidelines have been suggested
Precautions
CONTRAINDICATIONS:
-Hypersensitivity to active substance or any product excipients
-Known or suspected renal pathology (injection; due to presence of polyethylene glycol 300 in the vehicle)
Safety and efficacy or oral therapy have not been established in patients younger than 16 years.
Safety and efficacy or injectable therapy have not been established in patients younger than 18 years, except in tetanus.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
Oral Therapy: Take orally with or without food
Injectable Therapy:
-For IV and IM administration only; do not administer subcutaneously
-Total daily dose should not exceed 3 g per day (3 vials) for more than 3 consecutive days except in the treatment of tetanus; see below for special directions for use in tetanus
For IV Administration:
-May administer undiluted IV directly into vein at a maximum rate of 300 mg/minute (3 mL/minute)
-May dilute and administer via IV infusion using normal saline or D5W; 1 g (1 vial) should be diluted in no more than 250 mL
-Use caution to avoid vascular extravasation; this hypertonic solution may cause thrombophlebitis
-Patient should remain recumbent during and for at least 10 to 15 minutes following injection
For IM Administration:
-Inject no more than 500 mg (5 mL) into each gluteal region
-Injections may be repeated at 8-hour intervals; switch to oral therapy as soon as feasible
Special Directions for Use in Tetanus:
-Inject 1 or 2 g (10 or 20 mL) directly into tubing of inserted indwelling needle.
-Add 1 or 2 g (10 or 20 mL) to infusion bottle to allow for a total of 3 g (3 vials) as initial dose
Storage requirements:
-Once IV infusion is prepared: Do not refrigerate
IV compatibility: Compatible in normal saline and dextrose 5% solution
General:
-Polyethylene glycol 300 is present in the injectable formulation; large doses of polyethylene glycol 300 are known to increase preexisting acidosis and urea retention in patients with renal impairment; while the amount present is within the limits of safety, use is contraindicated in patients with renal impairment out of an abundance of caution.
Patient advice:
-Patients should understand that this drug may impair their mental and/or physical abilities to perform hazardous tasks such as driving, and they should be counseled appropriately.
-Patients should understand that this drug is a CNS depressant and patients should be cautioned about concomitant use of alcohol or other CNS depressants.
-Patients should be instructed to speak with their healthcare provider if they are pregnant, intending to become pregnant or breastfeeding.
Frequently asked questions
More about methocarbamol
- During Pregnancy or Patient Tips
Consumer resources
- Other brands
- Robaxin, Robaxin-750
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Diagnosing Benign Liver Masses
Relatively common in the liver, benign (noncancerous) liver masses or lesions may incidentally be detected on imaging studies, abnormal liver function tests, or during investigation of abdominal pain.
Symptoms of benign liver masses
Liver Mac Os X
Hemangiomas
- Pain often occurs in lesions greater than 5 to 6 centimeters in size
Hepatic adenomas
- Many people experience no symptoms
- Can be associated with birth control use
Focal nodular hyperplasia (FNH)
- Abdominal pain
Hepatic cysts (large)
- Abdominal pain or fullness
- A palpable mass
Testing for benign liver masses
Differentiating benign liver lesions from cancers can sometimes be done by radiologic imaging studies alone.
In addition to a physical exam, your doctor may order the following tests:
Imaging studies
Imaging studies, such as CT scans or abdominal ultrasounds, can show:
- The size and location of the lesion(s)
- Any blood clots in the major branches of the portal and hepatic veins
- Any enlarged lymph nodes
- Evidence of cirrhosis and its complications
- The vasculature structure surrounding the lesion
FNH lesions are usually well defined, with a typical “central scar” on CT scans.
Hepatic cystscan usually be differentiated from solid lesions by ultrasound or CT scans.
It's helpful to compare the size of the lesion to prior imaging studies (if they exist), to determine if the mass is growing. Follow-up imaging is important to ensure that the lesion is not enlarging.
Blood tests
Blood tests measure a complete blood cell count and assess how well your liver works. These include liver function tests, as well as tumor markers to evaluate your general health.
Biopsy
If the diagnosis is not clear, then often a liver biopsy is done to examine a sliver of the liver mass under the microscope. This outpatient procedure allows the liver pathologist t o determine the tissue diagnosis or if cancer cells are present.
Hemangiomas — Caution should be taken in ordering a liver biopsy if the suspected diagnosis is hemangioma, due to the risk of bleeding from the biopsy site, especially if the lesion is at the edge of the liver.
Mac Os Versions
To schedule an appointment, or for more information, call the UPMC Liver Cancer Center, toll-free, at 1-855-745-4837 (LIVER) or complete our contact form now.